Brentuximab vedotin with lenalidomide and rituximab is approved by the USFDA for relapsed or refractory large B-cell lymphoma
On February 11, 2025, the Food and Drug Administration authorized the use of brentuximab vedotin (Adcetris, Seagen Inc., a subsidiary of Pfizer) in conjunction with lenalidomide and a rituximab product for adult patients..
Acalabrutinib with bendamustine and rituximab is approved by the USFDA for previously untreated mantle cell lymphoma
On January 16, 2025, the Food and Drug Administration granted conventional approval to acalabrutinib (Calquence, AstraZeneca) in combination with bendamustine and rituximab for adults with previously untreated mantle cel..
The FDA has granted expedited approval to epcoritamab-bysp for the treatment of R/R follicular lymphoma
June 2024: The Food and Drug Administration has given accelerated approval to epcoritamab-bysp (Epkinly, Genmab US, Inc.), a bispecific CD20-directed CD3 T-cell engager, for adult patients with recurrent or refractory follicular l..
CAR T-Cell therapy for lymphoma
Introduction CAR T cell therapy has been a game-changer in the treatment of certain lymphomas, more so in patients relapsing or refractory to conventional therapies. This has been quite successful in targeting cancer cells within..
Lisocabtagene maraleucel is granted accelerated approval by FDA for follicular lymphoma
May 2015: Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been granted rapid approval by the Food and Drug Administration. This approval is specifically for people with relapsed or refractory follicular lymphoma..
Zanubrutinib is approved by the USFDA for relapsed or refractory follicular lymphoma
March 2024: Zanubrutinib (Brukinsa, BeiGene USA, Inc.) in combination with obinutuzumab has been granted accelerated approval by the Food and Drug Administration for the treatment of relapsed or refractory follicular lymphoma (FL)..
Pirtobrutinib is approved by the USFDA for chronic lymphocytic leukemia and small lymphocytic lymphoma
The Food and Drug Administration granted accelerated approval to pirtobrutinib (Jaypirca, Eli Lilly and Company) on December 1, 2023, for adults with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have u..
The Role Of Immunotherapy In Lymphoma Treatment
If you're reading this, you or maybe one of your loved ones is on a journey that no one ever plans to take—the path of facing cancer. We understand that this road is filled with uncertainties, fears, and moments when it feel..
CAR - T Cell therapy, CAR T Therapy, CAR T-Cell, chimeric agent
A Deep Dive into CAR T Cell Therapy: How Does It Work?
Discover the science behind CAR T Cell therapy treatment in India! Explore how this revolutionary treatment transforms your immune cells into cancer fighters. Read our blog now to learn more about this miraculous therapy and how..
CAR T-Cell, CAR therapy, Immunotherapy, T cell therapy
Is CAR T-Cell Therapy Available In India?
Have you ever wondered if there is a powerful way to fight cancer? Now just imagine if one day you found a ray of hope in your fight against cancer, a treatment that uses the power of your body's own immune system to target an..